|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's range||29.45 - 30.13|
|52-week range||17.20 - 34.29|
|Beta (5Y monthly)||1.23|
|PE ratio (TTM)||16.34|
|Earnings date||01 Nov 2021 - 05 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||34.33|
Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS). In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acquisition of Adamas is a smart move.
Peete and her daughter Ryan join forces to amplify the conversation around Attention-deficit/Hyperactivity disorder (ADHD) and neurodiversityNearly one-in-ten – or 6.1 million children and adolescents – are affected by ADHD ROCKVILLE, Md., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Actress, host, influencer, and mother, Holly Robinson Peete is partnering with Supernus Pharmaceuticals to raise awareness of Attention-deficit/Hyperactivity disorder (ADHD) – a neurodevelopmental condition that is one of the
Supernus Pharmaceuticals (NASDAQ:SUPN) has had a great run on the share market with its stock up by a significant 14...